Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Journal of Neurosurgical Sciences 2015 June;59(2) > Journal of Neurosurgical Sciences 2015 June;59(2):97-103

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

JOURNAL OF NEUROSURGICAL SCIENCES

A Journal on Neurosurgery


Indexed/Abstracted in: e-psyche, EMBASE, PubMed/MEDLINE, Neuroscience Citation Index, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,651


eTOC

 

ORIGINAL ARTICLES  


Journal of Neurosurgical Sciences 2015 June;59(2):97-103

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Determining need for treatment in residual pituitary adenomas

Davies G. M. 1, Huang C. 2, Sheehan J. M. 1

1 Department of Neurosurgery, Pennsylvania State University College of Medicine and Milton S. Hershey Medical Center, Hershey, PA, USA;
2 Pennsylvania State University College of Medicine, Hershey, PA, USA


PDF  


AIM: The optimal management of residual pituitary adenoma after resection is not clearly defined, with some authors proposing early radiosurgery or radiotherapy for patients with evidence of residual tumor on postoperative imaging and others recommending observation alone. This retrospective study seeks to determine the most appropriate treatment for patients with evidence of residual tumor on postoperative MRI.
METHODS: Forty-one consecutive patients who underwent transsphenoidal resection of pituitary adenomas between 2002 and 2005 and were followed radiographically and clinically for a mean of 4.4 years were analyzed.
RESULTS: Despite an official interpretation by a board-certified neuroradiologist suggesting the presence of residual tumor postoperatively in twenty-four out of forty-one patients, only four patients (16.7%) required additional intervention during the follow-up period. None of the patients received perioperative radiotherapy.
CONCLUSION: This suggests that aggressive management of radiographically suspected residual tumor may not be indicated and that observation with serial imaging may be sufficient in the management of patients with residual tumor.

top of page

Publication History

Cite this article as

Corresponding author e-mail

jsheehan@psu.edu